nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.234	0.391	CbGbCtD
Dabigatran etexilate—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0611	0.102	CbGbCtD
Dabigatran etexilate—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0552	0.0922	CbGbCtD
Dabigatran etexilate—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0477	0.0796	CbGbCtD
Dabigatran etexilate—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0463	0.0772	CbGbCtD
Dabigatran etexilate—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0419	0.0699	CbGbCtD
Dabigatran etexilate—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0419	0.0699	CbGbCtD
Dabigatran etexilate—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0401	0.067	CbGbCtD
Dabigatran etexilate—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0311	0.0518	CbGbCtD
Dabigatran etexilate—F2—endothelium—acquired immunodeficiency syndrome	0.00569	0.0641	CbGeAlD
Dabigatran etexilate—F2—blood plasma—acquired immunodeficiency syndrome	0.00506	0.0569	CbGeAlD
Dabigatran etexilate—UGT2B15—digestive system—acquired immunodeficiency syndrome	0.00355	0.04	CbGeAlD
Dabigatran etexilate—CES2—retina—acquired immunodeficiency syndrome	0.00309	0.0348	CbGeAlD
Dabigatran etexilate—CES2—skin of body—acquired immunodeficiency syndrome	0.00271	0.0305	CbGeAlD
Dabigatran etexilate—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00269	0.0303	CbGeAlD
Dabigatran etexilate—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.00217	0.0244	CbGeAlD
Dabigatran etexilate—CES2—digestive system—acquired immunodeficiency syndrome	0.00217	0.0244	CbGeAlD
Dabigatran etexilate—CES2—blood—acquired immunodeficiency syndrome	0.00206	0.0233	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—acquired immunodeficiency syndrome	0.002	0.0225	CbGeAlD
Dabigatran etexilate—CES2—spinal cord—acquired immunodeficiency syndrome	0.00199	0.0224	CbGeAlD
Dabigatran etexilate—F2—lymphoid tissue—acquired immunodeficiency syndrome	0.00197	0.0222	CbGeAlD
Dabigatran etexilate—F2—digestive system—acquired immunodeficiency syndrome	0.00194	0.0219	CbGeAlD
Dabigatran etexilate—CES2—vagina—acquired immunodeficiency syndrome	0.00191	0.0216	CbGeAlD
Dabigatran etexilate—F2—blood—acquired immunodeficiency syndrome	0.00185	0.0209	CbGeAlD
Dabigatran etexilate—NQO2—blood—acquired immunodeficiency syndrome	0.00185	0.0208	CbGeAlD
Dabigatran etexilate—CES2—lung—acquired immunodeficiency syndrome	0.00181	0.0204	CbGeAlD
Dabigatran etexilate—CES1—lymphoid tissue—acquired immunodeficiency syndrome	0.00181	0.0203	CbGeAlD
Dabigatran etexilate—F2—bone marrow—acquired immunodeficiency syndrome	0.00179	0.0202	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—acquired immunodeficiency syndrome	0.00179	0.0201	CbGeAlD
Dabigatran etexilate—CES1—digestive system—acquired immunodeficiency syndrome	0.00178	0.0201	CbGeAlD
Dabigatran etexilate—F2—spinal cord—acquired immunodeficiency syndrome	0.00178	0.0201	CbGeAlD
Dabigatran etexilate—NQO2—spinal cord—acquired immunodeficiency syndrome	0.00178	0.02	CbGeAlD
Dabigatran etexilate—NQO2—vagina—acquired immunodeficiency syndrome	0.00171	0.0193	CbGeAlD
Dabigatran etexilate—CES1—blood—acquired immunodeficiency syndrome	0.0017	0.0192	CbGeAlD
Dabigatran etexilate—CES2—nervous system—acquired immunodeficiency syndrome	0.00168	0.0189	CbGeAlD
Dabigatran etexilate—F2—lung—acquired immunodeficiency syndrome	0.00162	0.0183	CbGeAlD
Dabigatran etexilate—NQO2—lung—acquired immunodeficiency syndrome	0.00162	0.0182	CbGeAlD
Dabigatran etexilate—CES2—central nervous system—acquired immunodeficiency syndrome	0.00161	0.0182	CbGeAlD
Dabigatran etexilate—F2—nervous system—acquired immunodeficiency syndrome	0.0015	0.0169	CbGeAlD
Dabigatran etexilate—NQO2—nervous system—acquired immunodeficiency syndrome	0.0015	0.0169	CbGeAlD
Dabigatran etexilate—CES1—lung—acquired immunodeficiency syndrome	0.00149	0.0168	CbGeAlD
Dabigatran etexilate—F2—central nervous system—acquired immunodeficiency syndrome	0.00145	0.0163	CbGeAlD
Dabigatran etexilate—NQO2—central nervous system—acquired immunodeficiency syndrome	0.00144	0.0162	CbGeAlD
Dabigatran etexilate—CES1—nervous system—acquired immunodeficiency syndrome	0.00138	0.0155	CbGeAlD
Dabigatran etexilate—CES1—central nervous system—acquired immunodeficiency syndrome	0.00133	0.015	CbGeAlD
Dabigatran etexilate—CES2—brain—acquired immunodeficiency syndrome	0.00128	0.0144	CbGeAlD
Dabigatran etexilate—CES2—lymph node—acquired immunodeficiency syndrome	0.00124	0.0139	CbGeAlD
Dabigatran etexilate—F2—brain—acquired immunodeficiency syndrome	0.00115	0.0129	CbGeAlD
Dabigatran etexilate—NQO2—brain—acquired immunodeficiency syndrome	0.00114	0.0129	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—acquired immunodeficiency syndrome	0.00111	0.0125	CbGeAlD
Dabigatran etexilate—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00109	0.0122	CbGeAlD
Dabigatran etexilate—CES1—brain—acquired immunodeficiency syndrome	0.00106	0.0119	CbGeAlD
Dabigatran etexilate—CES1—lymph node—acquired immunodeficiency syndrome	0.00102	0.0115	CbGeAlD
Dabigatran etexilate—ABCB1—retina—acquired immunodeficiency syndrome	0.000595	0.00671	CbGeAlD
Dabigatran etexilate—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000423	0.00477	CbGeAlD
Dabigatran etexilate—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000418	0.00471	CbGeAlD
Dabigatran etexilate—ABCB1—blood—acquired immunodeficiency syndrome	0.000398	0.00449	CbGeAlD
Dabigatran etexilate—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000385	0.00434	CbGeAlD
Dabigatran etexilate—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000384	0.00432	CbGeAlD
Dabigatran etexilate—ABCB1—vagina—acquired immunodeficiency syndrome	0.000369	0.00416	CbGeAlD
Dabigatran etexilate—ABCB1—lung—acquired immunodeficiency syndrome	0.000349	0.00393	CbGeAlD
Dabigatran etexilate—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000328	0.00106	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.00106	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000327	0.00106	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000326	0.00106	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00106	CcSEcCtD
Dabigatran etexilate—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.00106	CcSEcCtD
Dabigatran etexilate—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00106	CcSEcCtD
Dabigatran etexilate—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000325	0.00105	CcSEcCtD
Dabigatran etexilate—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000324	0.00105	CcSEcCtD
Dabigatran etexilate—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000323	0.00364	CbGeAlD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000323	0.0953	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000323	0.00105	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000321	0.00104	CcSEcCtD
Dabigatran etexilate—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000321	0.00104	CcSEcCtD
Dabigatran etexilate—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.00032	0.00104	CcSEcCtD
Dabigatran etexilate—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000317	0.00103	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000317	0.00103	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000316	0.00103	CcSEcCtD
Dabigatran etexilate—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.00102	CcSEcCtD
Dabigatran etexilate—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.000316	0.00102	CcSEcCtD
Dabigatran etexilate—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.00102	CcSEcCtD
Dabigatran etexilate—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000312	0.00101	CcSEcCtD
Dabigatran etexilate—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000311	0.00351	CbGeAlD
Dabigatran etexilate—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000311	0.00101	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000311	0.00101	CcSEcCtD
Dabigatran etexilate—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000311	0.00101	CcSEcCtD
Dabigatran etexilate—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.00101	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000311	0.00101	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.00031	0.00101	CcSEcCtD
Dabigatran etexilate—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000308	0.000999	CcSEcCtD
Dabigatran etexilate—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000308	0.000999	CcSEcCtD
Dabigatran etexilate—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000308	0.000998	CcSEcCtD
Dabigatran etexilate—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.000998	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000306	0.000994	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000306	0.000991	CcSEcCtD
Dabigatran etexilate—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000305	0.00099	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000305	0.00099	CcSEcCtD
Dabigatran etexilate—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000305	0.000989	CcSEcCtD
Dabigatran etexilate—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000304	0.000985	CcSEcCtD
Dabigatran etexilate—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000304	0.000985	CcSEcCtD
Dabigatran etexilate—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000303	0.000984	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.000979	CcSEcCtD
Dabigatran etexilate—Rash—Didanosine—acquired immunodeficiency syndrome	0.000301	0.000977	CcSEcCtD
Dabigatran etexilate—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.000976	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000301	0.000976	CcSEcCtD
Dabigatran etexilate—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000301	0.000976	CcSEcCtD
Dabigatran etexilate—Cough—Ritonavir—acquired immunodeficiency syndrome	0.0003	0.000972	CcSEcCtD
Dabigatran etexilate—Headache—Didanosine—acquired immunodeficiency syndrome	0.000299	0.00097	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000299	0.000969	CcSEcCtD
Dabigatran etexilate—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000298	0.000968	CcSEcCtD
Dabigatran etexilate—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000298	0.000967	CcSEcCtD
Dabigatran etexilate—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000298	0.000965	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000297	0.000962	CcSEcCtD
Dabigatran etexilate—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000296	0.000961	CcSEcCtD
Dabigatran etexilate—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.000961	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000295	0.000957	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000295	0.000956	CcSEcCtD
Dabigatran etexilate—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.000954	CcSEcCtD
Dabigatran etexilate—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000294	0.000954	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000294	0.000953	CcSEcCtD
Dabigatran etexilate—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000293	0.000951	CcSEcCtD
Dabigatran etexilate—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000293	0.00095	CcSEcCtD
Dabigatran etexilate—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000948	CcSEcCtD
Dabigatran etexilate—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000948	CcSEcCtD
Dabigatran etexilate—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000291	0.000945	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.000942	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.000941	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000289	0.000938	CcSEcCtD
Dabigatran etexilate—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000289	0.000937	CcSEcCtD
Dabigatran etexilate—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000289	0.000937	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000289	0.000936	CcSEcCtD
Dabigatran etexilate—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000288	0.000935	CcSEcCtD
Dabigatran etexilate—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000288	0.000934	CcSEcCtD
Dabigatran etexilate—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000287	0.000929	CcSEcCtD
Dabigatran etexilate—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000286	0.000928	CcSEcCtD
Dabigatran etexilate—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000285	0.000925	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000285	0.000924	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000285	0.000923	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000284	0.00092	CcSEcCtD
Dabigatran etexilate—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000284	0.00092	CcSEcCtD
Dabigatran etexilate—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000283	0.000918	CcSEcCtD
Dabigatran etexilate—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000283	0.000917	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.000916	CcSEcCtD
Dabigatran etexilate—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000912	CcSEcCtD
Dabigatran etexilate—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000912	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00028	0.000906	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.000906	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000279	0.000904	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000899	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000276	0.000895	CcSEcCtD
Dabigatran etexilate—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000276	0.000894	CcSEcCtD
Dabigatran etexilate—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.000892	CcSEcCtD
Dabigatran etexilate—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000275	0.000892	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000275	0.000891	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000274	0.00089	CcSEcCtD
Dabigatran etexilate—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000274	0.000889	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000274	0.000889	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000273	0.000887	CcSEcCtD
Dabigatran etexilate—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000273	0.000885	CcSEcCtD
Dabigatran etexilate—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000273	0.000885	CcSEcCtD
Dabigatran etexilate—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000883	CcSEcCtD
Dabigatran etexilate—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000271	0.000878	CcSEcCtD
Dabigatran etexilate—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000271	0.000878	CcSEcCtD
Dabigatran etexilate—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000271	0.000877	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.000876	CcSEcCtD
Dabigatran etexilate—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00027	0.000876	CcSEcCtD
Dabigatran etexilate—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000269	0.000872	CcSEcCtD
Dabigatran etexilate—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00087	CcSEcCtD
Dabigatran etexilate—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.00087	CcSEcCtD
Dabigatran etexilate—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000869	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000267	0.000865	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000267	0.000864	CcSEcCtD
Dabigatran etexilate—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000266	0.000863	CcSEcCtD
Dabigatran etexilate—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000265	0.00086	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000265	0.000859	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000264	0.000858	CcSEcCtD
Dabigatran etexilate—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000264	0.000858	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000264	0.000856	CcSEcCtD
Dabigatran etexilate—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000264	0.000855	CcSEcCtD
Dabigatran etexilate—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000262	0.00085	CcSEcCtD
Dabigatran etexilate—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000262	0.00085	CcSEcCtD
Dabigatran etexilate—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.000849	CcSEcCtD
Dabigatran etexilate—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.000849	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000262	0.000848	CcSEcCtD
Dabigatran etexilate—Rash—Stavudine—acquired immunodeficiency syndrome	0.000261	0.000848	CcSEcCtD
Dabigatran etexilate—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000261	0.000847	CcSEcCtD
Dabigatran etexilate—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000261	0.000847	CcSEcCtD
Dabigatran etexilate—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000261	0.000845	CcSEcCtD
Dabigatran etexilate—Headache—Stavudine—acquired immunodeficiency syndrome	0.00026	0.000842	CcSEcCtD
Dabigatran etexilate—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00026	0.000842	CcSEcCtD
Dabigatran etexilate—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000259	0.00084	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.00084	CcSEcCtD
Dabigatran etexilate—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000259	0.000839	CcSEcCtD
Dabigatran etexilate—Rash—Abacavir—acquired immunodeficiency syndrome	0.000258	0.000835	CcSEcCtD
Dabigatran etexilate—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000257	0.000834	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000257	0.000834	CcSEcCtD
Dabigatran etexilate—Headache—Abacavir—acquired immunodeficiency syndrome	0.000256	0.00083	CcSEcCtD
Dabigatran etexilate—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000829	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000255	0.000828	CcSEcCtD
Dabigatran etexilate—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000255	0.000827	CcSEcCtD
Dabigatran etexilate—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000255	0.000827	CcSEcCtD
Dabigatran etexilate—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.000821	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000252	0.000818	CcSEcCtD
Dabigatran etexilate—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.000817	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000252	0.000817	CcSEcCtD
Dabigatran etexilate—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.000816	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00025	0.000812	CcSEcCtD
Dabigatran etexilate—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00081	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.00081	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000248	0.000803	CcSEcCtD
Dabigatran etexilate—ABCB1—brain—acquired immunodeficiency syndrome	0.000247	0.00278	CbGeAlD
Dabigatran etexilate—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000247	0.000801	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000247	0.000801	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000247	0.0008	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000247	0.0008	CcSEcCtD
Dabigatran etexilate—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000246	0.000799	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.000797	CcSEcCtD
Dabigatran etexilate—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000243	0.000787	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000242	0.000784	CcSEcCtD
Dabigatran etexilate—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000242	0.000783	CcSEcCtD
Dabigatran etexilate—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.000781	CcSEcCtD
Dabigatran etexilate—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00024	0.00078	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.00078	CcSEcCtD
Dabigatran etexilate—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.00078	CcSEcCtD
Dabigatran etexilate—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000777	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00024	0.000777	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000239	0.00269	CbGeAlD
Dabigatran etexilate—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000238	0.000773	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000237	0.00077	CcSEcCtD
Dabigatran etexilate—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000237	0.000769	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000234	0.00076	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000233	0.000757	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.000755	CcSEcCtD
Dabigatran etexilate—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.000754	CcSEcCtD
Dabigatran etexilate—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000748	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000744	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000229	0.000744	CcSEcCtD
Dabigatran etexilate—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000229	0.000743	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.000743	CcSEcCtD
Dabigatran etexilate—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000227	0.000737	CcSEcCtD
Dabigatran etexilate—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.000737	CcSEcCtD
Dabigatran etexilate—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000227	0.000736	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.000734	CcSEcCtD
Dabigatran etexilate—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000226	0.000732	CcSEcCtD
Dabigatran etexilate—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.000727	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000223	0.000724	CcSEcCtD
Dabigatran etexilate—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.000722	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.00072	CcSEcCtD
Dabigatran etexilate—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.000719	CcSEcCtD
Dabigatran etexilate—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000222	0.000719	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000222	0.000718	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000221	0.000715	CcSEcCtD
Dabigatran etexilate—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00022	0.000713	CcSEcCtD
Dabigatran etexilate—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.000705	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.000703	CcSEcCtD
Dabigatran etexilate—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000695	CcSEcCtD
Dabigatran etexilate—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000214	0.000695	CcSEcCtD
Dabigatran etexilate—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000214	0.000694	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.000691	CcSEcCtD
Dabigatran etexilate—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000213	0.000691	CcSEcCtD
Dabigatran etexilate—Rash—Indinavir—acquired immunodeficiency syndrome	0.000211	0.000685	CcSEcCtD
Dabigatran etexilate—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000211	0.000685	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000682	CcSEcCtD
Dabigatran etexilate—Headache—Indinavir—acquired immunodeficiency syndrome	0.00021	0.000681	CcSEcCtD
Dabigatran etexilate—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.000679	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000207	0.000672	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000206	0.000669	CcSEcCtD
Dabigatran etexilate—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000204	0.000663	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.00066	CcSEcCtD
Dabigatran etexilate—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000201	0.000653	CcSEcCtD
Dabigatran etexilate—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000652	CcSEcCtD
Dabigatran etexilate—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.00065	CcSEcCtD
Dabigatran etexilate—Rash—Efavirenz—acquired immunodeficiency syndrome	0.0002	0.000648	CcSEcCtD
Dabigatran etexilate—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.000647	CcSEcCtD
Dabigatran etexilate—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000199	0.000646	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.000644	CcSEcCtD
Dabigatran etexilate—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.000643	CcSEcCtD
Dabigatran etexilate—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.000643	CcSEcCtD
Dabigatran etexilate—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.000627	CcSEcCtD
Dabigatran etexilate—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000193	0.000625	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.000622	CcSEcCtD
Dabigatran etexilate—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000191	0.00062	CcSEcCtD
Dabigatran etexilate—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000191	0.000619	CcSEcCtD
Dabigatran etexilate—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000619	CcSEcCtD
Dabigatran etexilate—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.000616	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000615	CcSEcCtD
Dabigatran etexilate—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000188	0.00061	CcSEcCtD
Dabigatran etexilate—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.000601	CcSEcCtD
Dabigatran etexilate—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.000599	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.000598	CcSEcCtD
Dabigatran etexilate—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.00059	CcSEcCtD
Dabigatran etexilate—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00018	0.000584	CcSEcCtD
Dabigatran etexilate—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.000578	CcSEcCtD
Dabigatran etexilate—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000178	0.000578	CcSEcCtD
Dabigatran etexilate—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000177	0.000573	CcSEcCtD
Dabigatran etexilate—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000177	0.000572	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000571	CcSEcCtD
Dabigatran etexilate—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.000569	CcSEcCtD
Dabigatran etexilate—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000171	0.000556	CcSEcCtD
Dabigatran etexilate—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000552	CcSEcCtD
Dabigatran etexilate—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00017	0.000551	CcSEcCtD
Dabigatran etexilate—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00017	0.000551	CcSEcCtD
Dabigatran etexilate—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.000548	CcSEcCtD
Dabigatran etexilate—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.00054	CcSEcCtD
Dabigatran etexilate—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000164	0.00053	CcSEcCtD
Dabigatran etexilate—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000526	CcSEcCtD
Dabigatran etexilate—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000526	CcSEcCtD
Dabigatran etexilate—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.000523	CcSEcCtD
Dabigatran etexilate—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000519	CcSEcCtD
Dabigatran etexilate—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.000496	CcSEcCtD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—CXCL12—acquired immunodeficiency syndrome	0.000149	0.0439	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—CXCR4—acquired immunodeficiency syndrome	0.000149	0.0439	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—CCL5—acquired immunodeficiency syndrome	0.000113	0.0334	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000113	0.0332	CbGpPWpGaD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—IFNG—acquired immunodeficiency syndrome	8.35e-05	0.0246	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	7.8e-05	0.023	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	7.55e-05	0.0222	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	7.18e-05	0.0212	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	6.82e-05	0.0201	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	6.17e-05	0.0182	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL4—acquired immunodeficiency syndrome	6.15e-05	0.0181	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	5.75e-05	0.0169	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—ALB—acquired immunodeficiency syndrome	5.64e-05	0.0166	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—ENPEP—acquired immunodeficiency syndrome	5.33e-05	0.0157	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	5.01e-05	0.0148	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	4.57e-05	0.0135	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	4.57e-05	0.0135	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	4.21e-05	0.0124	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	4.14e-05	0.0122	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ALB—acquired immunodeficiency syndrome	4.08e-05	0.012	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	3.81e-05	0.0112	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TAT—acquired immunodeficiency syndrome	3.8e-05	0.0112	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.76e-05	0.0111	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	3.72e-05	0.011	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	3.58e-05	0.0106	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	3.58e-05	0.0106	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	3.48e-05	0.0103	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	3.34e-05	0.00985	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL2—acquired immunodeficiency syndrome	3.3e-05	0.00974	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	3.24e-05	0.00954	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AGPS—acquired immunodeficiency syndrome	3.23e-05	0.00953	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.15e-05	0.00928	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	3.01e-05	0.00886	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	2.96e-05	0.00872	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	2.95e-05	0.00871	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	2.95e-05	0.00869	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	2.9e-05	0.00855	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	2.9e-05	0.00855	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	2.83e-05	0.00833	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	2.72e-05	0.00803	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.69e-05	0.00792	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	2.55e-05	0.00753	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	2.51e-05	0.00741	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	2.45e-05	0.00724	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2.43e-05	0.00718	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.41e-05	0.00709	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.4e-05	0.00708	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.4e-05	0.00708	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.39e-05	0.00704	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.38e-05	0.00701	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.15e-05	0.00634	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.95e-05	0.00574	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.94e-05	0.00573	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.91e-05	0.00564	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	1.9e-05	0.00561	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	1.9e-05	0.00561	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	1.85e-05	0.00546	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.83e-05	0.00539	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.83e-05	0.00539	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.83e-05	0.00539	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	1.81e-05	0.00534	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.79e-05	0.00527	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.74e-05	0.00514	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TAT—acquired immunodeficiency syndrome	1.73e-05	0.00511	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.00485	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.62e-05	0.00476	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.57e-05	0.00462	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.55e-05	0.00457	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.54e-05	0.00455	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AGPS—acquired immunodeficiency syndrome	1.47e-05	0.00434	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TAT—acquired immunodeficiency syndrome	1.41e-05	0.00415	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.39e-05	0.0041	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.26e-05	0.0037	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.25e-05	0.0037	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.23e-05	0.00361	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.2e-05	0.00353	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	1.12e-05	0.0033	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.1e-05	0.00325	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.1e-05	0.00324	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.06e-05	0.00311	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.06e-05	0.00311	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.03e-05	0.00305	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.03e-05	0.00305	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.98e-06	0.00294	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	9.95e-06	0.00293	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.55e-06	0.00281	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.39e-06	0.00277	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.39e-06	0.00277	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—acquired immunodeficiency syndrome	7.99e-06	0.00235	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.86e-06	0.00232	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.75e-06	0.00228	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	7.55e-06	0.00223	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	7.25e-06	0.00214	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.14e-06	0.00211	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.09e-06	0.00209	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.03e-06	0.00207	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—acquired immunodeficiency syndrome	6.63e-06	0.00195	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.52e-06	0.00192	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—acquired immunodeficiency syndrome	6.48e-06	0.00191	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	6.46e-06	0.0019	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.43e-06	0.0019	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.9e-06	0.00174	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.55e-06	0.00163	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.55e-06	0.00163	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.51e-06	0.00162	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	5.49e-06	0.00162	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.22e-06	0.00124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.16e-06	0.00122	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.09e-06	0.00121	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.8e-06	0.00112	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.72e-06	0.0011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.58e-06	0.00105	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—acquired immunodeficiency syndrome	3.02e-06	0.00089	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	2.45e-06	0.000724	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.4e-06	0.000709	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.2e-06	0.000647	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.19e-06	0.000644	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.29e-06	0.00038	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.13e-06	0.000332	CbGpPWpGaD
